Alnylam Pharmaceuticals (ALNY) Slumps as Researchers Raise Red Flags
Shares of Alnylam Pharmaceuticals (Nasdaq: ALNY) slumped on Thursday. Traders say the stock's decline could relate to questions raised about treatments targeting alpha-synuclein. According to reports, drugs aimed at alpha-synuclein could be making people worse. Questions raise concerns about patients in clinical trials to lower alpha-synuclein.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: PetSmart (PETM) Sees Mid-Day Upside
- Hemispherx Biopharma (HEB) Reports Evidence Based Potential of Ampligen Against Ebola
- GW Pharma (GWPH) Commences Phase 2/3 Trial of Epidiolex
Create E-mail Alert Related CategoriesFDA, Rumors, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!